MediPharm Labs Corp. (LABS.TO)
| Previous close | 0.0800 |
| Open | 0.0850 |
| Bid | 0.0800 x N/A |
| Ask | 0.0850 x N/A |
| Day's range | 0.0800 - 0.0850 |
| 52-week range | 0.0550 - 0.1000 |
| Volume | |
| Avg. volume | 229,857 |
| Market cap | 32.324M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireMediPharm Labs Sets Date to Report First Quarter 2024 Financial Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.
Simply Wall St.MediPharm Labs Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
MediPharm Labs ( TSE:LABS ) Full Year 2023 Results Key Financial Results Revenue: CA$33.1m (up 50% from FY 2022). Net...
PR NewswireMediPharm Labs Provides Conference Call Recording Details
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
